FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130179360> ?p ?o ?g. }

• W3130179360 endingPage "S444" @default.
• W3130179360 startingPage "S444" @default.
• W3130179360 abstract "Neuromuscular blocking agents (NMBAs) are often administered to prevent patient movement during surgical procedures requiring use of general anesthetics, which can increase the risk of post-operative respiratory complications. Sugammadex is indicated to reverse neuromuscular blockade induced by rocuronium or vecuronium in adults and can efficiently reduce both moderate and deep levels of neuromuscular block. The aim of this study is to estimate clinical and economic impact of sugammadex in routine reversal of neuromuscular blockade with rocuronium in Spain. A budget impact model was developed to estimate the aggregated annual net budget impact of substituting sugammadex for neostigmine or no reversal agent in a proportion of patients administered with rocuronium. According to the local data, the annual number of hospital procedures in Spain was 733,876; 73.3% of them would use a NMBA. Rocuronium was administered in 64% of those procedures. Payer perspective was used in the analysis, including only the direct costs associated with post-operative pneumonias and atelectasis and drugs costs. One way sensitivity analysis was carried out by varying each parameter included in the model within a range of +/-50%. The estimated budget impact of the introduction of sugammadex to the routine reversal of neuromuscular blockade in Spanish hospitals was a net saving of €57.1 million annually. A rise in drug acquisition costs was offset by savings in post-operative respiratory events including 4,806 post-operative pneumonias and 13,996 cases of atelectasis. The total cost of complications avoided was €70.4 million. All scenarios tested in sensitivity analysis were favorable to the alternative scenario. Improving patient safety in the operation room is essential in surgical procedures where neuromuscular blocking agents with rocuronium are required. The clinical benefits in terms of avoided pneumonias and atelectasis with sugammadex would produce net savings for the Spanish National Healthcare System." @default.
• W3130179360 created "2021-03-01" @default.
• W3130179360 creator A5013872522 @default.
• W3130179360 creator A5019646391 @default.
• W3130179360 creator A5028534452 @default.
• W3130179360 creator A5059839434 @default.
• W3130179360 creator A5076063344 @default.
• W3130179360 creator A5076677051 @default.
• W3130179360 creator A5091826565 @default.
• W3130179360 date "2018-10-01" @default.
• W3130179360 modified "2023-09-30" @default.
• W3130179360 title "PSY52 - ECONOMIC IMPACT OF IMPROVING PATIENT SAFETY USING SUGAMMADEX FOR ROUTINE REVERSAL OF NEUROMUSCULAR BLOCKADE IN SPAIN" @default.
• W3130179360 doi "https://doi.org/10.1016/j.jval.2018.09.2629" @default.
• W3130179360 hasPublicationYear "2018" @default.
• W3130179360 type Work @default.
• W3130179360 sameAs 3130179360 @default.
• W3130179360 citedByCount "0" @default.
• W3130179360 crossrefType "journal-article" @default.
• W3130179360 hasAuthorship W3130179360A5013872522 @default.
• W3130179360 hasAuthorship W3130179360A5019646391 @default.
• W3130179360 hasAuthorship W3130179360A5028534452 @default.
• W3130179360 hasAuthorship W3130179360A5059839434 @default.
• W3130179360 hasAuthorship W3130179360A5076063344 @default.
• W3130179360 hasAuthorship W3130179360A5076677051 @default.
• W3130179360 hasAuthorship W3130179360A5091826565 @default.
• W3130179360 hasBestOaLocation W31301793601 @default.
• W3130179360 hasConcept C177713679 @default.
• W3130179360 hasConcept C2776277131 @default.
• W3130179360 hasConcept C2776988050 @default.
• W3130179360 hasConcept C2777411258 @default.
• W3130179360 hasConcept C2778560516 @default.
• W3130179360 hasConcept C2909465803 @default.
• W3130179360 hasConcept C2910841738 @default.
• W3130179360 hasConcept C42219234 @default.
• W3130179360 hasConcept C71924100 @default.
• W3130179360 hasConceptScore W3130179360C177713679 @default.
• W3130179360 hasConceptScore W3130179360C2776277131 @default.
• W3130179360 hasConceptScore W3130179360C2776988050 @default.
• W3130179360 hasConceptScore W3130179360C2777411258 @default.
• W3130179360 hasConceptScore W3130179360C2778560516 @default.
• W3130179360 hasConceptScore W3130179360C2909465803 @default.
• W3130179360 hasConceptScore W3130179360C2910841738 @default.
• W3130179360 hasConceptScore W3130179360C42219234 @default.
• W3130179360 hasConceptScore W3130179360C71924100 @default.
• W3130179360 hasLocation W31301793601 @default.
• W3130179360 hasOpenAccess W3130179360 @default.
• W3130179360 hasPrimaryLocation W31301793601 @default.
• W3130179360 hasRelatedWork W16745287 @default.
• W3130179360 hasRelatedWork W185446235 @default.
• W3130179360 hasRelatedWork W2127359424 @default.
• W3130179360 hasRelatedWork W2435571389 @default.
• W3130179360 hasRelatedWork W2586436858 @default.
• W3130179360 hasRelatedWork W2941521960 @default.
• W3130179360 hasRelatedWork W2985980400 @default.
• W3130179360 hasRelatedWork W3020171632 @default.
• W3130179360 hasRelatedWork W3134891845 @default.
• W3130179360 hasRelatedWork W4229007945 @default.
• W3130179360 hasVolume "21" @default.
• W3130179360 isParatext "false" @default.
• W3130179360 isRetracted "false" @default.
• W3130179360 magId "3130179360" @default.
• W3130179360 workType "article" @default.